Catherine A. Taylor,Zhongda Liu,Terence Tang,Richard S. Dondero,John E. Thompson
申请号：
US14398112
公开号：
US20150126582A1
申请日:
2013.04.30
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention relates to the treatment of multiple myeloma in a human subject comprising administering lenadlidomide in combination with a vector which expresses a human eIF-SAI which is unable to be hypusinated and an siRNA which targets eIF-SAI. In some embodiments, the lenalidomide is administered simultaneously with the vector and the siRNA while in some embodiments the lenalidomide is administered at a time that is different from when the vector and the siRNA are administered. In some embodiments, the lenalidomide is administered orally and the vector and the siRNA are administered intraveneously.
